GlaxoSmithKline PLC
LSE:GSK
GlaxoSmithKline PLC
LSE:GSK
Price:
2 204
GBX
-0.45%
Market Cap:
£89.8B
Relative Value
The Relative Value of one
GSK
stock under the Base Case scenario is
1 429.98
GBX.
Compared to the current market price of 2 204 GBX,
GlaxoSmithKline PLC
is
Overvalued by 35%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GSK
Relative Value
Base Case
1 429.98
GBX
Overvaluation 35%
Multiples Across Competitors
GSK Competitors Multiples
GlaxoSmithKline PLC Competitors
GlaxoSmithKline PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
89.9B GBP | 2.7 | 15.7 | 7.9 | 11.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
976.4B USD | 15 | 47.3 | 31.9 | 33.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.4B USD | 6.3 | 22 | 15.3 | 18.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
294.1B CHF | 4.8 | 31.4 | 13.2 | 15.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
249.1B CHF | 5.7 | 23 | 14.2 | 18.2 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.1B GBP | 5.4 | 31.3 | 17.3 | 24.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
306.5B USD | 4.7 | 16.8 | 10.5 | 12.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.2B USD | 2.5 | 19.8 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.7B USD | 2.6 | 17.5 | 7.3 | 9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
